Contraindication vs Precaution

In United States labelling these are two distinct sections with different evidentiary thresholds. Contraindications describe situations in which the drug should not be used because the risk clearly outweighs any possible benefit, and the section is deliberately short: it lists known hazards, not theoretical ones. Warnings and Precautions covers clinically significant risks that require discussion, monitoring, dose modification or avoidance in some patients, and is far longer. Clinicians also use the informal terms absolute and relative contraindication, which are bedside vocabulary rather than label categories.

GLP-1 receptor agonist labels show the split cleanly. Personal or family history of medullary thyroid carcinoma, and multiple endocrine neoplasia type 2, are contraindications, alongside prior serious hypersensitivity to the product. A history of pancreatitis sits instead in Warnings and Precautions: it was not studied, it raises concern, and it demands a conversation, but it does not bar treatment. Growth hormone labels contraindicate active malignancy and acute critical illness while listing intracranial hypertension and glucose intolerance as precautions.

The practical difference is that a contraindication ends the decision and a precaution reshapes it. One removes the option; the other changes what is monitored, how the dose is approached, what the patient is told, and what would prompt stopping.

Two opposite errors dominate. Clinics selling peptides often treat every precaution as a formality, screening for nothing and documenting less. Forums do the reverse, quoting any listed warning as though the drug were forbidden. A subtler error is quoting the phrase relative contraindication as though it appeared in the prescribing information; it does not, and using it misstates what the regulator concluded.